<DOC>
	<DOCNO>NCT00004482</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess effect immunosuppression muromonab-CD3 , cyclosporine , methylprednisolone , prednisone versus standard care term death , heart transplantation , leave ventricular assistive device placement patient giant cell myocarditis . II . Compare leave ventricular ejection fraction prior 4 week treatment arm . III . Compare degree myocardial inflammatory infiltrate prior 4 week treatment arm .</brief_summary>
	<brief_title>Phase II Randomized Study Muromonab-CD3 , Cyclosporine , Methylprednisolone , Prednisone Patients With Giant Cell Myocarditis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , open label , multicenter study . Patients randomize receive standard care immunosuppression ( arm I ) standard care without immunosuppression ( muromonab-CD3 cyclosporine ) ( arm II ) . Arm I : Patients receive methylprednisolone IV daily 3 day muromonab-CD3 IV daily 10 day . Oral cyclosporine administer twice daily oral prednisone administer daily 1 year . Arm II : Patients receive standard care without immunosuppression ( muromonab-CD3 cyclosporine ) . Patients follow one year .</detailed_description>
	<mesh_term>Myocarditis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Idiopathic giant cell myocarditis confirm endomyocardial biopsy Heart failure and/or arrhythmia less 3 month duration Patient Characteristics Hepatic : AST/ALT great 3 time upper limit normal Renal : Creatinine great 2.5 mg/dL Other : Not pregnant nursing ; Negative pregnancy test ; Fertile patient must use effective contraception ; No clinical evidence sepsis active infection ( e.g . meningitis , osteomyelitis , etc . ) ; No contraindication immunosuppression ; No allergy cyclosporine muromonabCD3 ; No severe concurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>giant cell myocarditis</keyword>
	<keyword>rare disease</keyword>
</DOC>